Latest News & Features
article
The 1999 Japanese Supreme Court judgment in the case of Ono Pharmaceuticals Co Ltd vs Kyoto Pharmaceutical Industries Ltd, held that carrying out necessary experiments to apply for approval of generic drugs stipulated in article 14 of the Pharmaceutical Affairs Act falls within “working of the patented invention for experiment or research”, however the original drugs are not mentioned. 4 November 2021
Americas
Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark. 4 November 2021
Generics
Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto. 4 November 2021
Medtech
The US Court of Appeals for the Federal Circuit has ruled that yet another CardioNet heart monitor patent is invalid for not citing an inventive concept under the Alice test. 2 November 2021
Americas
Medical device company Nevro has been hit with a $20m damages verdict after a US jury found that it had infringed two patents owned by Boston Scientific. 2 November 2021
Big Pharma
Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court. 2 November 2021
Big Pharma
UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC). 28 October 2021
Americas
Azurity Pharmaceuticals has sued Florida-based generic manufacturer CoreRx for infringing a pair of patents covering a hypertension drug for children. 28 October 2021
article
The US Patent Trial and Appeal Board (PTAB) has granted a review of a Novartis syringe patent following a challenge from biotech giant Regeneron. 28 October 2021
Medtech
Boston Scientific (BSC) and Nevro will testify before a Delaware Federal Court today following pleas from Nevro to delay the trial due to claims that BSC destroyed evidence related to a patent damages case. 26 October 2021